Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

Chronic Myeloid Leukaemia Patients with Stable Molecular Responses (at least MR3) May Safely Decrease the Dose of Their Tyrosine Kinase Inhibitor: Data from the British Destiny Study

Richard E. Clark, MD, Fotios Polydoros, MSc, Jane F. Apperley, MD, Christopher Pocock, Graeme Smith, MD, Jenny L Byrne, FRCP FRCPath PhD, Stephen G. O'Brien, BSc (Hons) PhD MBChB FRCP MRCPath, Tony Coffey, Letizia Foroni, MD PhD, Mhairi Copland, BSc (Hons) MB ChB PhDFRCP FRCPath

Blood (2016) 128 (22): 938.

https://doi.org/10.1182/blood.V128.22.938.938

Published: 2016

Journal Articles

The Real World Use of Bosutinib in Patients with Chronic Myeloid Leukaemia

Jane F. Apperley, MD, Jenny L. Byrne, FRCP FRCPath PhD, Graeme Smith, Simone Claudiani, Andrea Viqueira, Roxanne Ferdinand, Angela M Carter, Georgina Nock, Dragana Milojkovic

Blood (2016) 128 (22): 5435.

https://doi.org/10.1182/blood.V128.22.5435.5435

Published: 2016

Journal Articles

Assessment of Quality of Life in the NCRI Spirit 2 Study Comparing Imatinib with Dasatinib in Patients with Newly-Diagnosed Chronic Phase Chronic Myeloid Leukaemia

Alexander M. Labeit, MDPhD, Mhairi Copland, BSc (Hons) MB ChB PhDFRCP FRCPath, Leanne M. Cork, BSc (Hons), Corinne A. Hedgley, BSc (Hons), Letizia Foroni, MDPhDFRCPath, Wendy L. Osborne, MBBS (Hons) MRCP FRCPath, Gemma Gills, MSc BSc (Hons), Jane F. Apperley, MD, Tessa L. Holyoake, MDPhD, Ruth V. Bescoby, MSc BSc, Christopher Pocock, Thomas Zwingers, MSc, Philippa Burnell, Jenny L. Byrne, PhD, John H. McCullough, John M. Goldman, DM FRCP FRCPath, Richard E. Clark, MD, Stephen G. O'Brien, BSc (Hons) PhD MBChB FRCP MRCPath

Blood (2015) 126 (23): 4024.

https://doi.org/10.1182/blood.V126.23.4024.4024

Published: 2015

Journal Articles

Extracorporeal Photopheresis As Second Line Therapy for Steroid Refractory Acute Gvhd: Retrospective Study of Long-Term Outcomes

Rohini Radia, MBChB, Emma Das-Gupta, MD, Guillermo Orti, MD, Donal McLornan, MDPhD, Majid A. Kazmi, Christopher P Fox, PhD, Jenny L. Byrne, PhD, Nigel H. Russell, MD, Kavita Raj, MDPhD

Blood (2015) 126 (23): 1944.

https://doi.org/10.1182/blood.V126.23.1944.1944

Published: 2015

Journal Articles

Spirit 2: An NCRI Randomised Study Comparing Dasatinib with Imatinib in Patients with Newly Diagnosed CML

Stephen G O'Brien, BSc (Hons) PhD MBChB FRCP MRCPath, Corinne Hedgley, BSc, Sarah Adams, BSc MSc, Letizia Foroni, MDPhD, Jane F. Apperley, MD, Tessa L Holyoake, MDPhDFRSE FMedSci, Christopher Pocock, MD PhD, Jenny L Byrne, MB ChB PhDFRCP FRCPath, Lynn Margaret Seeley, MSc RN NDN, Wendy L Osborne, MBBS(Hons) MRCP FRCPath, John M Goldman, DM, Mhairi Copland, BSc PhDFRCP FRCPath, Richard E Clark, MA, MD

Blood (2014) 124 (21): 517.

https://doi.org/10.1182/blood.V124.21.517.517

Published: 2014

Journal Articles

Cyclophosphamide, thalidomide, and dexamethasone (CTD) as initial therapy for patients with multiple myeloma unsuitable for autologous transplantation

Gareth J. Morgan, Faith E. Davies, Walter M. Gregory, Nigel H. Russell, Sue E. Bell, Alexander J. Szubert, Nuria Navarro Coy, Gordon Cook, Sylvia Feyler, Jenny L. Byrne, Huw Roddie, Claudius Rudin, Mark T. Drayson, Roger G. Owen, Fiona M. Ross, Graham H. Jackson, J. Anthony Child, for the NCRI Haematological Oncology Study Group

Blood (2011) 118 (5): 1231–1238.

https://doi.org/10.1182/blood-2011-02-338665

Published: 2011

Includes: Supplemental data

Journal Articles

Posttransplantation imatinib as a strategy to postpone the requirement for immunotherapy in patients undergoing reduced-intensity allografts for chronic myeloid leukemia

Eduardo Olavarria, Shamyla Siddique, Michael J. Griffiths, Sharon Avery, Jenny L. Byrne, Karen P. Piper, Anne L. Lennard, Lalit Pallan, Julie M. Arrazi, Jolanta B. Perz, Derville O'Shea, John M. Goldman, Jane F. Apperley, Charles F. Craddock

Blood (2007) 110 (13): 4614–4617.

https://doi.org/10.1182/blood-2007-04-082990

Published: 2007

Journal Articles

Treatment of Enteropathy Associated T Cell Lymphoma with Combination Chemotherapy Followed by Autologous Stem Cell Transplantation.

Mark J. Bishton, Andrew P. Haynes, Jenny L. Byrne, Nigel H. Russell

Blood (2006) 108 (11): 5424.

https://doi.org/10.1182/blood.V108.11.5424.5424

Published: 2006

Journal Articles

Low Pre-DLI Lymphocytes Counts Are Predictive of Good Disease Responses in Patients with Mixed Chimerism Following Campath-Containing Reduced Intensity Transplants.

Bronwen E. Shaw, MRCPath, PhD, Jenny L. Byrne, MRCPath, PhD, Emma Das-Gupta, MRCP, PHD, Ian Carter, PhD, Nigel H. Russell

Blood (2006) 108 (11): 261.

https://doi.org/10.1182/blood.V108.11.261.261

Published: 2006

Journal Articles

Converting Mixed Chimerism to Full Donor Chimerism in Recipients of Campath-Containing Reduced Intensity Transplants Reduces the Relapse Risk and Results in Significantly Improved Survival Compared to Those with Persistent Full Donor Chimerism.

Bronwen E. Shaw, MRCP, PhD, Jenny L. Byrne, MRCP, PhD, Emma Das-Gupta, MRCP, PhD, Ian Carter, PhD, Nigel H. Russell, FRCPath, PhD

Blood (2005) 106 (11): 2026.

https://doi.org/10.1182/blood.V106.11.2026.2026

Published: 2005

Journal Articles

Single HLA Allele Mismatches Are Well Tolerated in the Recipients of T Cell Depleted Reduced Intensity Conditioned Transplants from Unrelated Donors.

Bronwen E. Shaw, MB, CHB, PhD, Nigel H. Russell, FRCPath, Steve Devereux, MRCPath, Das-Gupta Emma, MRCPath, PhD, Mackinnon Stephen, FRCPath, PhD, J.Alejandro Madrigal, FRCPath, PhD, Anthony Pagliuca, FRCPath, Ghulam J. Mufti, FRCPath, Jenny L. Byrne, MRCPath, PhD

Blood (2005) 106 (11): 2895.

https://doi.org/10.1182/blood.V106.11.2895.2895

Published: 2005

Journal Articles

High Response Rate to DLI Based Strategies for the Treatment of Refractory Disease/Relapse Following Allogeneic HSCT for Lymphoproliferative Disease.

Nigel H. Russell, MD, Jenny L. Byrne, PhD, Emma P. Das-Gupta, MD, Michelle Gilyead, BSc, Andy P. Haynes, MD

Blood (2004) 104 (11): 1653.

https://doi.org/10.1182/blood.V104.11.1653.1653

Published: 2004

NARROW

Chronic Myeloid Leukaemia Patients with Stable Molecular Responses (at least MR3) May Safely Decrease the Dose of Their Tyrosine Kinase Inhibitor: Data from the British Destiny Study

The Real World Use of Bosutinib in Patients with Chronic Myeloid Leukaemia

Assessment of Quality of Life in the NCRI Spirit 2 Study Comparing Imatinib with Dasatinib in Patients with Newly-Diagnosed Chronic Phase Chronic Myeloid Leukaemia

Extracorporeal Photopheresis As Second Line Therapy for Steroid Refractory Acute Gvhd: Retrospective Study of Long-Term Outcomes

Spirit 2: An NCRI Randomised Study Comparing Dasatinib with Imatinib in Patients with Newly Diagnosed CML

Cyclophosphamide, thalidomide, and dexamethasone (CTD) as initial therapy for patients with multiple myeloma unsuitable for autologous transplantation

Posttransplantation imatinib as a strategy to postpone the requirement for immunotherapy in patients undergoing reduced-intensity allografts for chronic myeloid leukemia

Treatment of Enteropathy Associated T Cell Lymphoma with Combination Chemotherapy Followed by Autologous Stem Cell Transplantation.

Low Pre-DLI Lymphocytes Counts Are Predictive of Good Disease Responses in Patients with Mixed Chimerism Following Campath-Containing Reduced Intensity Transplants.

Converting Mixed Chimerism to Full Donor Chimerism in Recipients of Campath-Containing Reduced Intensity Transplants Reduces the Relapse Risk and Results in Significantly Improved Survival Compared to Those with Persistent Full Donor Chimerism.

Single HLA Allele Mismatches Are Well Tolerated in the Recipients of T Cell Depleted Reduced Intensity Conditioned Transplants from Unrelated Donors.

High Response Rate to DLI Based Strategies for the Treatment of Refractory Disease/Relapse Following Allogeneic HSCT for Lymphoproliferative Disease.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only